HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.
Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML
https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml Phase